Form 4: VolitionRx CEO Plans Future Stock Purchase
Planned Insider Stock Purchase
VolitionRx CEO Cameron John Reynolds reported a planned acquisition of 20,000 common shares at $0.35 per share, effective November 17, 2025, under a Rule 10b5-1 plan.
Summary
- Cameron John Reynolds, President and CEO, Director, and 10% owner of VolitionRx Ltd. (VNRX), reported a planned acquisition of company common stock.
- The transaction involves the purchase of 20,000 shares at a price of $0.35 per share.
- The transaction date is November 17, 2025.
- This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
- Following this planned transaction, Mr. Reynolds will beneficially own 2,554,847 shares directly, 1,007,718 shares indirectly through Concord International, Inc., and 34,076 shares indirectly through his spouse, totaling 3,596,641 shares.
Sentiment
Score: 7
Explanation: The planned insider purchase by the CEO, especially under a 10b5-1 plan, generally signals management's confidence in the company's future performance and valuation, which is a positive indicator for investors.
Positives
- The CEO's planned purchase of 20,000 shares indicates confidence in the company's future prospects.
- The transaction is being executed under a Rule 10b5-1 plan, suggesting a pre-planned, systematic approach to increasing insider ownership.
Negatives
- NA
Risks
- NA
Future Outlook
The filing indicates a pre-planned acquisition of shares by the CEO on November 17, 2025, under a Rule 10b5-1 plan, suggesting a structured approach to increasing insider ownership in the future and signaling management's long-term confidence.
Management Comments
- The CEO's planned purchase of shares under a 10b5-1 plan signals a long-term commitment and belief in the company's value.
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- The CEO, Cameron John Reynolds, is increasing his direct beneficial ownership.
- Indirect beneficial ownership is reported through Concord International, Inc., where Mr. Reynolds is the majority shareholder, and through his spouse.
Stakeholder Impact
- Shareholders: Increased insider ownership may be viewed positively, signaling management's belief in the company's value and future prospects.
Next Steps
- Execution of the planned acquisition of 20,000 common shares by Cameron John Reynolds on November 17, 2025.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Date of earliest transaction (planned acquisition of 20,000 common shares by CEO Cameron John Reynolds). |
Recommendation
buyThe planned purchase by the CEO, especially at the stated price and under a 10b5-1 plan, suggests strong insider confidence in the company's valuation and future prospects. This insider buying activity often serves as a positive signal to the market, indicating that management believes the stock is undervalued or poised for growth.
Keywords
VNRX, VolitionRx, insider trading, Form 4, stock purchase, CEO, Cameron John Reynolds, 10b5-1 plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.